RENE Stock Overview
ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
ReNeuron Group plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.034 |
| 52 Week High | UK£0.11 |
| 52 Week Low | UK£0.033 |
| Beta | 0.69 |
| 1 Month Change | 0% |
| 3 Month Change | -12.34% |
| 1 Year Change | -59.82% |
| 3 Year Change | -97.56% |
| 5 Year Change | -98.93% |
| Change since IPO | -99.87% |
Recent News & Updates
Recent updates
We Think ReNeuron Group (LON:RENE) Needs To Drive Business Growth Carefully
Jul 15
We're Keeping An Eye On ReNeuron Group's (LON:RENE) Cash Burn Rate
Jan 22Companies Like ReNeuron Group (LON:RENE) Can Afford To Invest In Growth
Oct 12Will ReNeuron Group (LON:RENE) Spend Its Cash Wisely?
Jun 04Is ReNeuron Group (LON:RENE) In A Good Position To Deliver On Growth Plans?
Jan 12
Here's What We Learned About The CEO Pay At ReNeuron Group plc (LON:RENE)
Nov 20Shareholder Returns
| RENE | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | -0.4% | 2.2% |
| 1Y | -59.8% | -29.1% | 0.9% |
Return vs Industry: RENE underperformed the UK Biotechs industry which returned -29.5% over the past year.
Return vs Market: RENE underperformed the UK Market which returned 0.6% over the past year.
Price Volatility
| RENE volatility | |
|---|---|
| RENE Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: RENE has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine RENE's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 26 | n/a | www.reneuron.com |
ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized vesicles secreted by stem cells.
ReNeuron Group plc Fundamentals Summary
| RENE fundamental statistics | |
|---|---|
| Market cap | UK£1.93m |
| Earnings (TTM) | -UK£5.07m |
| Revenue (TTM) | UK£249.00k |
7.7x
P/S Ratio-0.4x
P/E RatioIs RENE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RENE income statement (TTM) | |
|---|---|
| Revenue | UK£249.00k |
| Cost of Revenue | UK£3.65m |
| Gross Profit | -UK£3.40m |
| Other Expenses | UK£1.67m |
| Earnings | -UK£5.07m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.089 |
| Gross Margin | -1,367.47% |
| Net Profit Margin | -2,037.35% |
| Debt/Equity Ratio | 0% |
How did RENE perform over the long term?
See historical performance and comparison